R1 RCM Stock Forecast, Price & News

+0.29 (+1.31 %)
(As of 06/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.58 million shs
Average Volume1.51 million shs
Market Capitalization$5.86 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RCM News and Ratings via Email

Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter.

R1 RCM logo

About R1 RCM

R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. It also provides modular services comprising physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. It serves healthcare providers, including health systems, hospitals, and physician groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was incorporated in 2003 and is headquartered in Chicago, Illinois.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.58 out of 5 stars

Finance Sector

601st out of 1,979 stocks

Management Services Industry

2nd out of 12 stocks

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

R1 RCM (NASDAQ:RCM) Frequently Asked Questions

Is R1 RCM a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" R1 RCM stock.
View analyst ratings for R1 RCM
or view top-rated stocks.

What stocks does MarketBeat like better than R1 RCM?

Wall Street analysts have given R1 RCM a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but R1 RCM wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting R1 RCM?

R1 RCM saw a increase in short interest in May. As of May 28th, there was short interest totaling 5,100,000 shares, an increase of 43.3% from the May 13th total of 3,560,000 shares. Based on an average trading volume of 1,780,000 shares, the days-to-cover ratio is presently 2.9 days. Currently, 4.3% of the company's shares are short sold.
View R1 RCM's Short Interest

When is R1 RCM's next earnings date?

R1 RCM is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for R1 RCM

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) released its quarterly earnings data on Tuesday, May, 4th. The healthcare provider reported ($2.37) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.08 by $2.45. The healthcare provider had revenue of $342.60 million for the quarter, compared to analysts' expectations of $338.74 million. R1 RCM had a trailing twelve-month return on equity of 74.82% and a net margin of 9.65%. The business's quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.05 EPS.
View R1 RCM's earnings history

How has R1 RCM's stock price been impacted by Coronavirus (COVID-19)?

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RCM stock has increased by 120.3% and is now trading at $22.38.
View which stocks have been most impacted by COVID-19

What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM updated its FY 2021 earnings guidance on Tuesday, May, 18th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $1.41 billion-$1.46 billion, compared to the consensus revenue estimate of $1.45 billion.

What price target have analysts set for RCM?

6 brokerages have issued twelve-month target prices for R1 RCM's shares. Their forecasts range from $22.00 to $35.00. On average, they expect R1 RCM's stock price to reach $28.83 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price.
View analysts' price targets for R1 RCM
or view top-rated stocks among Wall Street analysts.

Who are R1 RCM's key executives?

R1 RCM's management team includes the following people:
  • Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 50, Pay $1.05M)
  • Ms. Rachel Wilson, Exec. VP, CFO & Treasurer (Age 48, Pay $349.68k) (LinkedIn Profile)
  • Mr. Richard B. Evans Jr., Sr. VP, Corp. Controller & Chief Accounting Officer (Age 53, Pay $393.27k)
  • Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 50, Pay $692.74k) (LinkedIn Profile)
  • Mr. John M. Sparby, Exec. VP of Operations & Delivery and COO (Age 45) (LinkedIn Profile)
  • Mr. Atif A. Rahim, Sr. VP of Investor Relations & Bus. Devel.
  • Mr. Corey Perman, Exec. VP of Compliance & Risk (LinkedIn Profile)
  • Mr. Sean Radcliffe, Exec. VP, Gen. Counsel & Corp. Sec. (LinkedIn Profile)
  • Mr. Vijay Kumar Kotte, Exec. VP of Strategy & Corp. Devel. and Chief Solutions Officer (Age 43) (LinkedIn Profile)
  • Ms. Kate Sanderson, Exec. VP & Chief HR Officer (LinkedIn Profile)

What is Joseph Flanagan's approval rating as R1 RCM's CEO?

253 employees have rated R1 RCM CEO Joseph Flanagan on Joseph Flanagan has an approval rating of 70% among R1 RCM's employees.

Who are some of R1 RCM's key competitors?

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.52%), Paradigm Capital Management Inc. NY (1.47%), Bank of New York Mellon Corp (1.04%), Geode Capital Management LLC (0.77%), Nuveen Asset Management LLC (0.74%) and Praesidium Investment Management Company LLC (0.64%). Company insiders that own R1 RCM stock include Achi Series Lllp Tcp-Asc, Albert Rene Zimmerli, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan and Michael C Feiner.
View institutional ownership trends for R1 RCM

Which institutional investors are selling R1 RCM stock?

RCM stock was sold by a variety of institutional investors in the last quarter, including Eaton Vance Management, SCW Capital Management LP, Bank of New York Mellon Corp, Clearbridge Investments LLC, Panagora Asset Management Inc., Boston Partners, Glenmede Trust Co. NA, and Royce & Associates LP. Company insiders that have sold R1 RCM company stock in the last year include Achi Series Lllp Tcp-Asc, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, and Michael C Feiner.
View insider buying and selling activity for R1 RCM
or view top insider-selling stocks.

Which institutional investors are buying R1 RCM stock?

RCM stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Allianz Asset Management GmbH, Millennium Management LLC, Renaissance Technologies LLC, Arrowstreet Capital Limited Partnership, Geode Capital Management LLC, Compagnie Lombard Odier SCmA, and Mirae Asset Global Investments Co. Ltd.. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan.
View insider buying and selling activity for R1 RCM
or or view top insider-buying stocks.

How do I buy shares of R1 RCM?

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $22.38.

How much money does R1 RCM make?

R1 RCM has a market capitalization of $5.86 billion and generates $1.27 billion in revenue each year. The healthcare provider earns $117.10 million in net income (profit) each year or $0.28 on an earnings per share basis.

How many employees does R1 RCM have?

R1 RCM employs 20,200 workers across the globe.

Does R1 RCM have any subsidiaries?

The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Advanced Data Processing Inc., Cerner RevWorks, Intermedix, Intermedix ARM LLC, Intermedix Analytics LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Physician Services LLC, Intermedix Staffing Inc., Med Media Inc., Medical Consultants Inc., Optima (NZ) Limited, Optima (US) LTD, Practice Support Resources LLC, Project Links Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCI Solutions, The DeZonia Group Inc., The Optima Corporation (International) LTD, The Optima Corporation Limited, and The Optima Corporation PTY LTD.

When was R1 RCM founded?

R1 RCM was founded in 2003.

What is R1 RCM's official website?

The official website for R1 RCM is

Where are R1 RCM's headquarters?

R1 RCM is headquartered at 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611.

How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at (312) 324-7820 or via email at [email protected]

This page was last updated on 6/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.